Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study looks for genes that may raise the risk of lymphoma, a cancer of immune cells. It uses a tumor and data bank to compare lymphoma that runs in families with lymphoma that does not. It is for adults with certain blood or immune cell cancers and a family history of cancer, and their family members.
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- You must be older than 18.
- You have non-Hodgkin lymphoma, Hodgkin disease, or chronic lymphocytic leukemia (CLL), and a parent, brother, sister, or child has a disorder in which immune cells grow too much.
- Or, you have a disorder in which immune cells grow too much, and your family has an unusual number of solid tumors or solid tumors at unusually young ages.
- Family members with or without lymphoma may join if the person with cancer contacts them and they agree to take part.
- Family members who have died may also be included. Public records may confirm their health history. Their closest relative must give permission to use medical records or stored tissue samples, which may be used to study genes.
Who can't join
- You have no family history of lymphoma.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed. * Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study. * Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research. * Age \> 18 years Exclusion Criteria: * Subjects without a family history of lymphoma
Study sites (1)
MA
- Dana-Farber Cancer Institute · Boston, MA 02115Jennifer R. Brown, MD, PhD · Study contact · 617-632-6692 · jennifer_brown@dfci.harvard.eduJennifer R. Brown, MD, PhD · Principal investigatorMore trials in Boston